Citadel Advisors’s VIVEVE MED INC VIVE Stock Holding History

Citadel Advisors’s Portfolio VIVE Stock Details VIVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-23	Closed	-$61K	–	9979
2018 Q3	$61K	Buy	+23	New	+$65.2K	﹤0.01%	8760

Other funds holding VIVE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's VIVE Position: Q3 2022 in Review

Citadel Advisors sold out of VIVEVE MED INC (VIVE) in Q3 2022, closing a stake of 25,740 shares — an estimated $17K sold.

Citadel Advisors first reported a position in VIVE in Q4 2018 and held it in 6 quarters. The position peaked at $90K in Q1 2021. 15 funds tracked by Wall St. Rank hold VIVE as of Q3 2022.

Citadel Advisors reported no remaining VIVEVE MED INC position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 25,740 VIVEVE MED INC shares in Q3 2022, an estimated $17K.
Citadel Advisors first reported a position in VIVEVE MED INC in Q4 2018 and held it in 6 quarters.
Citadel Advisors's VIVEVE MED INC position peaked at $90K in Q1 2021.
15 funds tracked by Wall St. Rank held VIVEVE MED INC as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.